Comparison of epoetin alfa (EPO) and darbepoetin alfa (DARB) utilization in cancer chemotherapy patients treated in a hospital outpatient setting

被引：0

|

作者：

Vekeman, F.

LaFeuille, M.

Bailey, R.

Piech, C. Tak

McKenzie, R. S.

Lefebvre, P.

机构：

[1] Grp Analyse Ltd, Montreal, PQ, Canada

[2] Centocor Ortho Biotech Serv LLC, Horsham, PA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e17524

引用

收藏

页数：1

相关论文

共 50 条

[1] Utilization of epoetin alfa (EPO) and darbepoetin alfa (DARB) in critically ill patients.
Mody, S.
Watson, S.
McKenzie, R. S.
Raut, M.
[J]. CRITICAL CARE MEDICINE, 2006, 34 (12) : A131 - A131
[2] Hospital inpatient utilization of epoetin alfa (EPO) and darbepoetin alfa (DARB) in patients with cancer and pre-dialysis chronic kidney disease (PCKD)
Smith, J
He, J
Mahoney, A
Noone, P
Watson, S
Mody, S
McKenzie, RS
[J]. VALUE IN HEALTH, 2006, 9 (03) : A105 - A105
[3] COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN A CHRONIC KIDNEY DISEASE POPULATION TREATED IN THE HOSPITAL OUTPATIENT SETTING
Vekeman, Francis
McKenzie, R. Scott
Lafeuille, Marie-Helene
Bailey, Robert A.
Piech, Catherine Tak
Lefebvre, Patrick
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (04) : A78 - A78
[4] COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN A CHRONIC KIDNEY DISEASE POPULATION TREATED IN THE HOSPITAL INPATIENT AND OUTPATIENT SETTING
Lafeuille, Marie-Helene
Bailey, Robert A.
Senbetta, Mekre
Lefebvre, Patrick
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (04) : A56 - A56
[5] Evaluation of dosing and clinical response to darbepoetin alfa (DA) and epoetin alfa (EPO) in patients treated for chemotherapy-induced anemia in hospital oncology outpatient clinics.
Gupta, V
Rago, MA
Goetz, A
Fastenau, J
Watson, S
[J]. BLOOD, 2003, 102 (11) : 509B - 509B
[6] Regarding "randomized comparison of epoetin alfa and darbepoetin alfa in anemic patients with cancer receiving chemotherapy"
Nowrousian, Mohammad Resa
[J]. ONCOLOGIST, 2006, 11 (05): : 535 - 536
[7] Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia
Herrington, JD
Davidson, SL
Tomita, DK
Green, L
Smith, RE
Boccia, RV
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (01) : 54 - 62
[8] Better early and overall hematologic outcomes and lower drug cost with epoetin alfa (EPO) compared with darbepoetin alfa (DARB).
Mark, TL
McKenzie, SR
Piech, CT
[J]. BLOOD, 2003, 102 (11) : 510B - 510B
[9] Regarding "randomized comparison of epoetin alfa and darbepoetin alfa in anemic patients with cancer receiving chemotherapy" - In Reply
Waltzman, Roger
[J]. ONCOLOGIST, 2006, 11 (05): : 536 - 537
[10] Propensity score matched evaluation of epoetin alfa and darbepoetin alfa utilization in patients with cancer receiving chemotherapy.
Bailey, R. A.
Tunceli, O.
Singer, J.
Stephenson, J. J.
Senbetta, M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →